Staniforth D H, Yorkston N J, Gemidjioglu M
Eur J Clin Pharmacol. 1980 Jun;17(6):415-8. doi: 10.1007/BF00570157.
No correlation was found between blood glucose and simultaneous measurements of plasma propranolol concentration in patients with schizophrenia, on a daily dose of 80 mg to 1800 mg of propranolol as an adjunct to phenothiazine medication. The Glucose Tolerance Test (GTT) in ten patients on propranolol and phenothiazines did not differ significantly from those of a matched control group on phenothiazine alone. Two patients with mild diabetes showed no significant change in their GTT after stopping propranolol. These observations accord with the view that relatively high doses of propranolol as an adjunct to phenothiazine medication in schizophrenia are safe from the standpoint of glucose metabolism. This does not apply to the insulin dependent diabetic who is in danger of severe hypoglycaemia when glycogenolysis is blocked by propranolol.
在接受每日80毫克至1800毫克普萘洛尔作为吩噻嗪类药物辅助治疗的精神分裂症患者中,未发现血糖与同时测量的血浆普萘洛尔浓度之间存在相关性。10名服用普萘洛尔和吩噻嗪类药物的患者的葡萄糖耐量试验(GTT)与仅服用吩噻嗪类药物的匹配对照组相比,无显著差异。两名轻度糖尿病患者在停用普萘洛尔后,其GTT无显著变化。这些观察结果与以下观点一致,即从葡萄糖代谢的角度来看,相对高剂量的普萘洛尔作为精神分裂症患者吩噻嗪类药物的辅助用药是安全的。这不适用于胰岛素依赖型糖尿病患者,因为当普萘洛尔阻断糖原分解时,这类患者有发生严重低血糖的危险。